Trials / Active Not Recruiting
Active Not RecruitingNCT03069378
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talimogene Laherparepvec (T-VEC) | Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter . |
| DRUG | Pembrolizumab | Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter. |
Timeline
- Start date
- 2017-03-03
- Primary completion
- 2025-07-22
- Completion
- 2026-03-01
- First posted
- 2017-03-03
- Last updated
- 2025-10-29
- Results posted
- 2025-10-29
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03069378. Inclusion in this directory is not an endorsement.